The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.
 
Lisa M. Gudenkauf
No Relationships to Disclose
 
Melody Chavez
No Relationships to Disclose
 
Melinda Maconi
No Relationships to Disclose
 
Carley Geiss
Employment - HCA Healthcare (I)
 
Ameen Seyedroudbari
No Relationships to Disclose
 
Pan Thin
No Relationships to Disclose
 
Aasha Hoogland
No Relationships to Disclose
 
Kathleen Nguyen
No Relationships to Disclose
 
Laura B. Oswald
No Relationships to Disclose
 
Heather S.L. Jim
Consulting or Advisory Role - Janssen Medical Affairs; Merck
Research Funding - Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Methods of Treating Cognitive Impairment, United States Letters Patent No. 10806772, 10/20/2020
 
Ghassan El-Haddad
Consulting or Advisory Role - Bayer; Boston Scientific; Canon Medical System; Curium Pharma; Novartis; TERUMO
 
Wolfgang Peter Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; Janssen
Speakers' Bureau - Bayer; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - Aktis Oncology; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bain Capital; Bayer; BTG; GE Healthcare; IPSEN; ITG (Inst); Novartis; ROTOP Pharmaka (Inst); Siemens Healthineers
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Celcuity; Fulcrum Therapeutics; GlaxoSmithKline; Immunogen; Ipsen; Novartis; Pfizer
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); PledPharma (Inst); Regeneron (Inst)
 
Johannes Czernin
Leadership - Momentum Biosciences; SOFIE
Stock and Other Ownership Interests - Momentum Biosciences; SOFIE; Trethera
Consulting or Advisory Role - Actinium Pharmaceuticals; POINT Biopharma
 
Michael S Hofman
Consulting or Advisory Role - Endocyte; Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Bayer (Inst); Endocyte (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen
 
Adam P. Dicker
Stock and Other Ownership Interests - Oncohost
Consulting or Advisory Role - Alcimed; Aptar Pharma; CVS; Deallus; EmpiricaLab; Genentech; Hengrui Pharmaceutical; IBA; Janssen; Oncohost; Onconova Therapeutics; Orano Med; SBR Biotechnologies
Patents, Royalties, Other Intellectual Property - We recently filed a patient "DOPED BEO COMPOUNDS FOR OPTICALLY STIMULATED LUMINESCENCE (OSL) AND THERMOLUMINESCENCE (TL) RADIATION DOSIMETRY"
Expert Testimony - Wilson Sonsini
Travel, Accommodations, Expenses - Oncohost
Other Relationship - European Commission
(OPTIONAL) Uncompensated Relationships - Dreamit Ventures; Google
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; EXINI Diagnostics; Progenics; Radiomedix
Consulting or Advisory Role - Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; POINT Biopharma; Progenics; Telix Pharmaceuticals
Speakers' Bureau - IBA RadioPharma Solutions; Telix Pharmaceuticals
Research Funding - Progenics
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Brian D. Gonzalez
Stock and Other Ownership Interests - Elly Health
Consulting or Advisory Role - KemPharm; Sure Med Compliance
Patents, Royalties, Other Intellectual Property - US Trademark Serial Number 88480263 (virtual reality software)